| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8215395 | International Journal of Radiation Oncology*Biology*Physics | 2016 | 9 Pages |
Abstract
NCCN high-risk prostate cancer patients who meet VHR criteria experience distinctly worse outcomes following definitive radiation and long-term androgen deprivation therapy, particularly if an EOR PSA is detectable. Optimal use of local therapies for VHR patients should be explored further, as should novel agents.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Amol K. MD, Carol BA, Scott P. PhD, Pei PhD, Ashwin N. MD, Todd R. PhD, Emily BA, Theodore A. BA, Stephanie BS, Harleen BA, Danny Y. MD, Phuoc T. MD, PhD, Theodore L. MD,